Boehringer Ingelheim

Icon makes senior appointments

Monday, May 21, 2012 11:52 AM

Icon, a global provider of outsourced development services, has appointed Dr. Susan Anton as director of epidemiology and risk management practice, Icon late phase & outcomes research, and Dr. Pui Leung as senior clinical research physician, Icon Development Solutions.

More... »


Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »


Paul Fonteyne named president, CEO of Boehringer Ingelheim USA

Friday, February 10, 2012 11:42 AM

Paul R. Fonteyne has been promoted to U.S. country managing director and president and CEO of Boehringer Ingelheim USA. Fonteyne assumes this role from J. Martin Carroll, who remains with the company in a corporate strategy and development role and a member of the board.

More... »

Boehringer Ingelheim, GWT and TU Dresden sign diabetes research collaboration

Tuesday, February 7, 2012 11:14 AM

Boehringer Ingelheim, GWT and the Department of Medicine of the TU Dresden have signed a research collaboration agreement to develop new insights into the causes of diabetes and the link between excessive blood glucose, the hallmark of diabetes, and the serious complications of the disease that can affect many organ functions.

More... »

ACRP names new academy trustees

Thursday, January 26, 2012 04:03 AM

The Academy of Clinical Research Professionals (ACRP) has appointed the following individuals to serve as members of the Academy Board of Trustees for a one-year term of office as of Jan. 1, 2012:

More... »

Russia's cancer drug market to grow to $163 million

Wednesday, December 14, 2011 12:48 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has found that the Russian market for non-small-cell lung cancer therapies will grow 3% annually from 2010 to 2015 to $163 million in 2015. According to the Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.

More... »

Coldstream Laboratories names VP of manufacturing

Tuesday, November 22, 2011 01:37 PM

Coldstream Laboratories, a provider of drug product research and manufacturing services, has named Dr. Vickie Hall vice president of manufacturing. Hall will assume responsibility of Coldstream's manufacturing, facilities, and warehouse operations.

More... »

FDA approves Combivent Respimat for COPD

Tuesday, October 11, 2011 12:11 PM

Boehringer Ingelheim Pharmaceuticals has reported that the FDA has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler (COMBIVENT MDI). COMBIVENT RESPIMAT will be available for patients in mid-2012.

More... »

Boehringer Ingelheim creates biosmiliars division

Tuesday, September 27, 2011 01:36 PM

Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that market, according to InPharm.

More... »

Nuevolution, Boehringer collaborate in drug discovery

Tuesday, September 20, 2011 12:22 PM

Nuevolution has entered into a collaboration with Boehringer Ingelheim, using Nuevolution’s proprietary Chemetics drug discovery technology.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs